glaxosmithkline - Latest News, Analysis, Opinion

Companies & Markets Sector Reports Retail

Dove soap maker Unilever signalled on Monday it would pursue a deal for GlaxoSmithKline's consumer health business

Can We Afford This Wave?

Dr S S Mantha

Economy

People too are tired of all the restrictions, the loss of wages, loss of esteem and fatigue. More than 50% of the cases have originated in Maharashtra and its cities, defying normal logic.

GSK Pharma Board Approves Sale Of Vemgal Plant To Hetero Labs

Shares of GlaxoSmithKline Pharmaceuticals were trading at Rs 1,430.35 per scrip on BSE, up 0.38 per cent over previous close.

GSK, Sanofi Begin New COVID-19 Vaccine Trial After Setback Last Year

Sanofi and GSK's candidate uses the same recombinant protein-based technology as one of Sanofi's seasonal influenza vaccines.

Sanofi Says Could Help Produce Competitors' COVID-19 Shots

Sanofi and Britain's GlaxoSmithKline said a COVID-19 vaccine they are jointly developing had showed an insufficient immune response in older people, delaying its launch to late next year, in a setback for both companies.

Wall Street Banks See Rare Payday Bonanza In India Despite Pandemic

Companies & Markets Markets

India saw $16.8 billion of mergers and acquisitions (M&A) in its technology, media, and telecoms (TMT) sector between January and mid-October, up 62% percent from the same time last year

GSK To Launch Late-Stage Testing Of Syncytial Virus Vaccine

RSV vaccine development has been fraught with setbacks for decades but the pharma industry is gearing up to bring a first inoculation to market over the next few years.

AstraZeneca's Asthma Drug Succeeds Late-Stage Study

Chronic rhinosinusitis with nasal polyps (CRSwNP) is characterised by a persistent inflammation of the mucous membrane lining the nasal passages and sinuses accompanied by benign growths.

Sanofi Eyes Approval Of COVID-19 Vaccine By First Half Of 2021

Sanofi, which is hosting a virtual research and development event, and GSK had said in April the vaccine, if successful, would be available in the second half of 2021.

GSK In Quest To Be Best, Not First, In Race For COVID-19 Vaccine

GSK is one of more than 100 global players working on vaccines against COVID-19, which has killed about 350,000 people.

GSK Aims For 1 Billion Doses With COVID Vaccine Booster Plan

GSK is working on its own COVID vaccine with French drugmaker Sanofi, one of the many projects to counter the respiratory illness that currently that has no treatment and has killed about 350,000 people.

GSK's Long-Acting Injection Beats Truvada In HIV Prevention Trial

Truvada generated $2.8 billion in sales last year, both from treatment and preventing an HIV infection.

GSK Sells $3.35 Billion Stake In Hindustan Unilever

The deal, at $3.35 billion, eclipses the previous block trade record in India when Daiichi Sankyo sold its $3.18 billion stake in Sun Pharmaceuticals in April 2015

GSK Profit Beats On Shingrix, Demand For Pain Meds During Pandemic